Comparative intravitreal Conbercept versus Ranibizumab in macular edema secondary to retinal vein occlusion: a Meta-analysis

AIM: To compare the efficacy and safety of intravitreal conbercept and ranibizumab in the treatment of macular edema secondary to retinal vein occlusion(RVO-ME)in order to provide basis for clinical guidance.<p>METHODS: The Cochrane Library, Embase, Web of Science, and CNKI, Wanfang data, and...

Full description

Bibliographic Details
Main Authors: Li Peng, Xiao-Hua Zhang, Na Lao, Qing Xie
Format: Article
Language:English
Published: Press of International Journal of Ophthalmology (IJO PRESS) 2020-03-01
Series:Guoji Yanke Zazhi
Subjects:
Online Access:http://ies.ijo.cn/cn_publish/2020/3/202003011.pdf
_version_ 1818035698015404032
author Li Peng
Xiao-Hua Zhang
Na Lao
Qing Xie
author_facet Li Peng
Xiao-Hua Zhang
Na Lao
Qing Xie
author_sort Li Peng
collection DOAJ
description AIM: To compare the efficacy and safety of intravitreal conbercept and ranibizumab in the treatment of macular edema secondary to retinal vein occlusion(RVO-ME)in order to provide basis for clinical guidance.<p>METHODS: The Cochrane Library, Embase, Web of Science, and CNKI, Wanfang data, and VIP database were comprehensively searched for studies comparing conbercept versus ranibizumab in patients with RVO-ME. Best-corrected visual acuity(BCVA), central macular thickness(CMT), intraocular pressure(IOP), mean number of intravitreal injections and adverse events were extracted from the final eligible studies. RevMan 5.3 software was used for relevant index data analysis. Random and fixed effect models were employed to evaluate heterogeneity and the publication bias.<p>RESULTS: A total of 14 randomized controlled trial(RCT)studies, involving 1 350 eyes. There was no significant difference in BCVA improved between the two groups after treatment 2wk, 2mo, 3mo and 6mo, but there was significant difference in BCVA improved after treatment 1wk [WMD=-0.03; 95% <i>CI</i>(-0.05, -0.02); <i>P</i><0.0001] and 1mo [WMD=-0.03; 95% <i>CI</i>(-0.04, -0.01); <i>P</i>=0.001]. The conbercept treatment group had higher CMT reduction compared with ranibizumab treatment group after 6mo treatment, and there was a significant difference [WMD=-28.77; 95% <i>CI</i>(-54.23, -3.31); <i>P</i>=0.03], and there were no significant difference between two groups in others period of time. There were no significant difference in intraocular pressure(IOP)and adverse events between the two groups [<i>OR</i>=0.95; 95% <i>CI</i>(0.57, 1.57); <i>P</i>=0.84]. However, the use of conbercept had a fewer mean number of injections.<p>CONCLUSION: CMT and BCVA were improved significantly both in the conbercept and ranibizumab groups. Compared with ranibizumab, conbercept group did not have greater improved BCVA, but with a more CMT reduction after 6mo. The advantage of conbercept is fewer injections and maybe it is better for treatment of RVO-ME.
first_indexed 2024-12-10T06:59:11Z
format Article
id doaj.art-c0f3ef64037343f189d48b1210e1ed8c
institution Directory Open Access Journal
issn 1672-5123
1672-5123
language English
last_indexed 2024-12-10T06:59:11Z
publishDate 2020-03-01
publisher Press of International Journal of Ophthalmology (IJO PRESS)
record_format Article
series Guoji Yanke Zazhi
spelling doaj.art-c0f3ef64037343f189d48b1210e1ed8c2022-12-22T01:58:21ZengPress of International Journal of Ophthalmology (IJO PRESS)Guoji Yanke Zazhi1672-51231672-51232020-03-0120345546310.3980/j.issn.1672-5123.2020.3.11Comparative intravitreal Conbercept versus Ranibizumab in macular edema secondary to retinal vein occlusion: a Meta-analysisLi Peng0Xiao-Hua Zhang1Na Lao2Qing Xie3Department of Ophthalmology, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Haikou People's Hospital, Haikou 570208, Hainan Province, China; Department of Ophthalmology, the Second Xiangya Hospital, Central South University, Changsha 410000, Hunan Province, ChinaDepartment of Ophthalmology, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Haikou People's Hospital, Haikou 570208, Hainan Province, ChinaDepartment of Ophthalmology, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Haikou People's Hospital, Haikou 570208, Hainan Province, ChinaDepartment of Ophthalmology, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Haikou People's Hospital, Haikou 570208, Hainan Province, ChinaAIM: To compare the efficacy and safety of intravitreal conbercept and ranibizumab in the treatment of macular edema secondary to retinal vein occlusion(RVO-ME)in order to provide basis for clinical guidance.<p>METHODS: The Cochrane Library, Embase, Web of Science, and CNKI, Wanfang data, and VIP database were comprehensively searched for studies comparing conbercept versus ranibizumab in patients with RVO-ME. Best-corrected visual acuity(BCVA), central macular thickness(CMT), intraocular pressure(IOP), mean number of intravitreal injections and adverse events were extracted from the final eligible studies. RevMan 5.3 software was used for relevant index data analysis. Random and fixed effect models were employed to evaluate heterogeneity and the publication bias.<p>RESULTS: A total of 14 randomized controlled trial(RCT)studies, involving 1 350 eyes. There was no significant difference in BCVA improved between the two groups after treatment 2wk, 2mo, 3mo and 6mo, but there was significant difference in BCVA improved after treatment 1wk [WMD=-0.03; 95% <i>CI</i>(-0.05, -0.02); <i>P</i><0.0001] and 1mo [WMD=-0.03; 95% <i>CI</i>(-0.04, -0.01); <i>P</i>=0.001]. The conbercept treatment group had higher CMT reduction compared with ranibizumab treatment group after 6mo treatment, and there was a significant difference [WMD=-28.77; 95% <i>CI</i>(-54.23, -3.31); <i>P</i>=0.03], and there were no significant difference between two groups in others period of time. There were no significant difference in intraocular pressure(IOP)and adverse events between the two groups [<i>OR</i>=0.95; 95% <i>CI</i>(0.57, 1.57); <i>P</i>=0.84]. However, the use of conbercept had a fewer mean number of injections.<p>CONCLUSION: CMT and BCVA were improved significantly both in the conbercept and ranibizumab groups. Compared with ranibizumab, conbercept group did not have greater improved BCVA, but with a more CMT reduction after 6mo. The advantage of conbercept is fewer injections and maybe it is better for treatment of RVO-ME.http://ies.ijo.cn/cn_publish/2020/3/202003011.pdfconbercpteranibizumabmacular edema secondary to retinal vein occlusionmeta-analysisefficacysafety
spellingShingle Li Peng
Xiao-Hua Zhang
Na Lao
Qing Xie
Comparative intravitreal Conbercept versus Ranibizumab in macular edema secondary to retinal vein occlusion: a Meta-analysis
Guoji Yanke Zazhi
conbercpte
ranibizumab
macular edema secondary to retinal vein occlusion
meta-analysis
efficacy
safety
title Comparative intravitreal Conbercept versus Ranibizumab in macular edema secondary to retinal vein occlusion: a Meta-analysis
title_full Comparative intravitreal Conbercept versus Ranibizumab in macular edema secondary to retinal vein occlusion: a Meta-analysis
title_fullStr Comparative intravitreal Conbercept versus Ranibizumab in macular edema secondary to retinal vein occlusion: a Meta-analysis
title_full_unstemmed Comparative intravitreal Conbercept versus Ranibizumab in macular edema secondary to retinal vein occlusion: a Meta-analysis
title_short Comparative intravitreal Conbercept versus Ranibizumab in macular edema secondary to retinal vein occlusion: a Meta-analysis
title_sort comparative intravitreal conbercept versus ranibizumab in macular edema secondary to retinal vein occlusion a meta analysis
topic conbercpte
ranibizumab
macular edema secondary to retinal vein occlusion
meta-analysis
efficacy
safety
url http://ies.ijo.cn/cn_publish/2020/3/202003011.pdf
work_keys_str_mv AT lipeng comparativeintravitrealconberceptversusranibizumabinmacularedemasecondarytoretinalveinocclusionametaanalysis
AT xiaohuazhang comparativeintravitrealconberceptversusranibizumabinmacularedemasecondarytoretinalveinocclusionametaanalysis
AT nalao comparativeintravitrealconberceptversusranibizumabinmacularedemasecondarytoretinalveinocclusionametaanalysis
AT qingxie comparativeintravitrealconberceptversusranibizumabinmacularedemasecondarytoretinalveinocclusionametaanalysis